Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAESAREA, Israel--(BUSINESS WIRE)--Itamar-Medical Ltd (TASE: ITAMAR), developer and marketer of the EndoPATTM non-invasive device for the assessment of endothelial function, today announced that The AMA (American Medical Association) has awarded a CPT category III reimbursement code to a test performed by its EndoPAT proprietary device.
Help employers find you! Check out all the jobs and post your resume.
CAESAREA, Israel--(BUSINESS WIRE)--Itamar-Medical Ltd (TASE: ITAMAR), developer and marketer of the EndoPATTM non-invasive device for the assessment of endothelial function, today announced that The AMA (American Medical Association) has awarded a CPT category III reimbursement code to a test performed by its EndoPAT proprietary device.
Help employers find you! Check out all the jobs and post your resume.
